Introduction {#sec1}
============

Esophageal carcinoma is the eighth most common diagnosed malignoma worldwide \[[@bib1]\]. The incidence of esophageal adenocarcinomas (EACs) has increased rapidly mainly in the Western world over the past few decades \[[@bib2], [@bib3], [@bib4]\]. Most of the adenocarcinomas arise from Barrett metaplasia due to chronic reflux disease followed by an accumulation of different mutations, copy-number variations, and chromothripsis causing genetic instability \[[@bib5]\]. Despite improvements in perioperative treatments, the overall survival (OS) of patients with EACs remains poor showing a relative 5-year survival rate of about 20.2%. Among the most common mutations of the EACs are *TP53*, *CDKN2A*, and *ARID1a* \[[@bib6]\].

Interestingly, these and other mutations can already be detected in histologically inconspicuous Barrett\'s mucosa without dysplasia. The extent of mutations of a dysplastic Barrett mucosa is similar to that of EAC \[[@bib7], [@bib8], [@bib9], [@bib10]\]. Another example for very early occurring mutations can be seen for *TP53* and *NOTCH1*, as such mutations are found in normal esophageal squamous cell epithelium in healthy volunteers. The probability of mutation increases with age and the extent of *NOTCH1*-mutations is greater than the expected rate of invasive esophageal squamous cell carcinoma \[[@bib11]\].

There is growing evidence that copy-number alterations (CNAs) of the genome are the major pathophysiological differences between Barrett\'s mucosa and invasive adenocarcinoma of the esophagus \[[@bib12],[@bib13]\]. The most common single loss-of-heterozygosity CNA seen in Barrett\'s mucosa is *CDK2NA* \[[@bib14],[@bib15]\].

Copy-number gains (CNGs) are common in the EAC. According to the TCGA data, considering genomic data of approximately 185 EACs, there are putative CNGs among others in *Her2* (in up to 15%), *VEGFA* (14%), *EGFR* (14%), *MET* (4%), *c-MYC* (22%), *GATA6* (12%), *KRAS* (17%), and *PIK3CA* (18%) (compare [http://cancergenome.nih.gov/](https://cancergenome.nih.gov/){#intref0010}) \[[@bib16], [@bib17], [@bib18]\].

Activating mutations of *KRAS* and *PIK3CA* (or function-inhibiting genomic alterations of *PTEN*) increase the activity of important growth-promoting cancer pathways (RAS-RAF-ERK pathway or PIK-AKT-mTOR pathway). Various studies have shown that CNG/amplification of *KRAS* and *PIK3CA* lead to an activation of these pathways even without additional activating mutations in the genes themselves. According to the TCGA data and other publications, activating gene mutations and amplifications are exclusive (with rare exceptions) \[[@bib19], [@bib20], [@bib21]\]. Recently, the therapeutic relevance of a *KRAS* amplification in wild-type (nonmutated) *KRAS* tumors of the upper gastrointestinal tract was highlighted and a therapeutic intervention with a combined inhibition of MEK and SHP2 was discussed \[[@bib22]\].

Therapeutic interventions of the activated PIK-AKT pathway have been discussed as well and resistance to cisplatin-containing cytostatic therapy is described in ovarian cancer with amplification of PIK3CA mRNA \[[@bib23]\].

There are no established findings on the prognostic significance of *KRAS* and *PIK3CA* amplification in primary resected or neoadjuvantly treated EACs and their correlation with the inflammatory tumor microenvironment \[[@bib24]\].

In colon carcinoma and non--small-cell lung carcinoma, a relationship to mutations and CNA and specific reactions of the (inflammatory) tumor microenvironment was shown \[[@bib25], [@bib26], [@bib27], [@bib28], [@bib29]\]. Interactions of the activated PIK-AKT pathway with the inflammatory tumor microenvironment have been shown in the past in other tumor entities like colon or ovarian carcinoma \[[@bib30],[@bib31]\]. Activation of *AKT* leads to the recruitment of different inflammatory cells including CD8 positive T lymphocytes. This interaction is partly because of activation of the NF-kappaB pathway and activation of cyclooxygenase, leading to formation of prostaglandin E2, which enables its receptor to recruit certain T-cell subpopulations \[[@bib32],[@bib33]\].

Particularly good response rates to immunotherapy can be found in gastric carcinoma or colon carcinoma in the group of microsatellite-instable tumors (MSIs), histologically typically associated with a strong inflammation in the tumor microenvironment, but this subtype is very rare in the EAC (1%) \[[@bib29],[@bib34],[@bib35]\].

Nevertheless, we see a high variability in the extent of inflammation in the EACs of our tumor collection, but did not correlate molecular alterations of the carcinoma cells yet \[[@bib36], [@bib37], [@bib38], [@bib39]\]. Thus we examined whether we find interactions between *PIK3CA* amplifications, leading to activation of the AKT pathway, and the recruitment of T lymphocytes into the tumor microenvironment of EAC. Furthermore, we evaluated the frequency of *KRAS* amplification in EAC. In addition, we analyzed the role of potential tumor escape mechanisms against T-cell recruitment by locally immunosuppressive checkpoint markers such as PD-L1, VISTA, LAG3, TIM3, and IDO. Therefore, we performed fluorescence in situ hybridization (FISH) and immunohistochemistry of 685 EACs, allowing us to accurately determine the extent of gene amplifications on a very large tumor cohort and correlated these results with clinical and additional molecular data and the composition of the inflammatory tumor microenvironment.

Material and Methods {#sec2}
====================

Patients and Tumor Samples {#sec2.1}
--------------------------

We analyzed formalin-fixed and paraffin-embedded (FFPE) material of 685 patients with EAC in total that underwent primary surgical resection or resection after neoadjuvant therapy between 1999 and 2016 at the Department of General, Visceral and Cancer Surgery, University of Cologne, Germany. The standard surgical procedure consisted of a transthoracic en-bloc esophagectomy with two-field lymphadenectomy (abdominal and mediastinal lymph nodes), reconstruction was done by formation of a gastric tube with intrathoracic esophagogastrostomy (Ivor Lewis esophagectomy) \[[@bib40]\]. The abdominal phase was predominantly performed as a laparoscopic procedure (hybrid Ivor Lewis esophagectomy). Technical details of this operation are described elsewhere \[[@bib41], [@bib42], [@bib43]\]. Patients with advanced esophageal cancer (cT3, cNx, M0) received preoperative chemoradiation (5-FU, cisplatin, 40Gy as treated in the area prior the CROSS trial) or chemotherapy alone. The follow-up of all patients was performed according to a standardized protocol. During the first two years, clinical follow-up of patients was performed in the hospital every three months, followed by annual exams. These included clinical evaluation, abdominal ultrasound, chest X-ray, and additional diagnostic procedures as required. Follow-up data were available for all patients. Patient characteristics are given in [Table 1](#tbl1){ref-type="table"}. Depending on the effect of neoadjuvant chemo- or radiochemotherapy, there is a preponderance of minor responders in the tissue microarrays (TMAs), defined as histopathological residual tumor of ≥10% \[[@bib44]\].Table 1Patients\' Characteristics, *KRAS* (*n* = 526) and *PIK3CA* (*n* = 461) Amplification Status.Table 1KRASPIK3CATotalNegativeAmplified*p* valueTotalNegativeAmplified*p* valueTotal5264329446143724100%82.1%17.9%100%94.8%5.5%SexFemale595095453111.2%84.7%15.3%11.7%98.1%1.9%Male467382854073842388.8%81.8%18.2%0.71988.3%94.3%5.7%0.339Age group\<65 yrs261217442252121352.6%83.1%16.9%48.8%94.2%5.8%\<65 yrs235188472122011147.4%80.0%20.0%0.41651.2%94.8%5.2%0.836Tumor stagepT17463116356714.1%85.1%14.9%13.7%88.9%11.1%pT26049115148311.5%81.7%18.3%11.1%94.1%5.9%pT3370302683303171370.6%81.6%18.4%71.7%96.1%3.9%pT418144141313.4%77.8%22.2%0.8803.0%92.9%7.1%0.217Lymph node metastasispN0209184251811691239.9%88.0%12.0%39.4%93.4%6.6%pN+315246692782661260.1%78.1%21.9%0.00460.6%95.7%4.3%0.290UICC stageI11499159485921.8%86.8%13.2%20.6%90.4%9.6%II1149816106101521.8%86.0%14.0%23.2%95.3%4.7%III21817147192184841.8%78.4%21.6%42.0%95.8%4.2%IV7660166563214.6%78.9%21.1%0.14614.2%96.9%3.1%0.198Her2 statusWild type311252592742561888.1%81.0%19.0%87.8%93.4%6.6%Amplified424023836211.9%95.2%4.8%0.02712.2%94.7%5.30%1.00TP53 statusWild type15513817136129741.6%89.0%11.0%41.6%94.9%5.10%Mutation218173451911791258.4%46.4%12.1%0.01658.4%54.7%3.70%0.812

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

TMA Construction {#sec2.2}
----------------

For TMA, one tissue core from each tumor was punched out and transferred into a TMA-recipient block. TMA construction was performed as previously described \[[@bib45],[@bib46]\]. In brief, tissue cylinders with a diameter of 1.2 mm each were punched from selected tumor tissue blocks using a self-constructed semiautomated precision instrument and embedded in empty recipient paraffin blocks.

Consecutive sections of the resulting TMA blocks were transferred to an adhesive-coated slide system (Instrumedics Inc., Hackensack, NJ) for immunohistochemistry and FISH.

Analysis of Heterogeneity of Amplification {#sec2.3}
------------------------------------------

To clarify the important question of the heterogeneous distribution of amplified tumor clones, we further analyzed all amplified tumors on large tumor surfaces and constructed a heterogeneity tissue microarray (h-TMA) of 48 tumors. This h-TMA contains each three KRAS- and PIK3CA-amplified tumors, which were also analyzed on large surfaces, and additional 45 nonamplified tumors. Standard TMAs typically use one biopsy per tumor, whereas the h-TMA takes into account up to 12 biopsies per tumor. In tumors without lymphonodal metastases (*n* = 25) we punched out four biopsies from the tumor surface and four from the infiltration zone of the tumor periphery. In lymphonodal positive tumors (*n* = 23), four additional biopsies were taken from the lymph node biopsies.

Immunohistochemistry {#sec2.4}
--------------------

The KRAS antibody (clone 9.13, Thermo Fisher, dilution 1:100) and PIK3CA antibody (clone 6D9, Thermo Fisher, dilution 1:1000) stainings were performed on TMA slides using the Ventana Benchmark stainer (Roche Diagnostics, Germany) according to the protocol of the manufacturers. Expression of KRAS and PIK3CA in the cytoplasm of carcinoma cells were assessed according to the following criteria: negative or weak staining in \<5% of tumor cells (score 0); weak staining ≥5--20% of tumor cells (score 1); moderate to strong staining in ≥20% (score 2; compare [Figure 3](#fig3){ref-type="fig"}). The evaluation of immunohistochemical expression was assessed manually by two pathologists (A.Q. and A.E.). Discrepant results, which occurred in a small number of samples, were resolved by consensus review. Additional immunohistochemical markers were evaluated in this cohort of EAC, parts of it (VISTA, CD3) published \[[@bib39]\], others (PD-L1, LAG3, TIM3, IDO) are currently under review. In brief, monoclonal antibodies were used (Ventana: PD-L1; Cell Signaling Technology: LAG3, TIM3, IDO) on the Ventana Benchmark stainer (PD-L1) or the Leica BOND-MAX stainer (Leica Biosystems, Germany) (LAG3, TIM3, and IDO). The expression in \<1% lymphocytes were defined as negative and ≥1% was assessed as positive.

Fluorescence *In Situ* Hybridization {#sec2.5}
------------------------------------

FISH for the evaluation of the *KRAS* gene amplification status was performed with the Zytolight SPEC KRAS/CEN12 Dual Color Probe (Zytovision, Germany) according to the manufacturers\' protocol. For *PIK3CA* gene amplification analysis, the Zytolight SPEC PIK3CA/CEN3 Dual Probe Kit (Zytovision, Germany) was used according to the manufacturers\' protocol. Sample processing was performed as described previously \[[@bib47]\]. Tumor tissue was scanned for gene copy gains including chromosomal cluster amplifications hot spots using a 63× objective (DM5500 fluorescent microscope; Leica, Germany). In case the signals were homogeneously distributed, then random areas were used for counting the signals. Twenty tumor cells were evaluated by counting green *KRAS* or *PIK3CA* and orange centromere signals. The reading strategy for detecting amplifications followed the recommendations *KRAS/CEN12* ratio \>3.0 or *KRAS* extrachromosomal cluster amplifications signals \[[@bib48]\]. For *PIK3CA* reading strategy followed the recommendations of previous studies *PIK3CA*/CEN3 ratio ≥2.0 or *PIK3CA* signals ≥5.0 proof an amplification \[[@bib49],[@bib50]\].

Statistical Analysis {#sec2.6}
--------------------

Clinical data were collected prospectively according to a standardized protocol. For statistical analysis, SPSS Statistics for Mac (Version 21, SPSS) was used. Interdependence between staining and clinical data was calculated using the chi-squared and Fisher\'s exact tests and displayed by cross tables. Survival curves were plotted using the Kaplan--Meier method and analyzed using the log-rank test.

Results {#sec3}
=======

Clinicopathological and Patients\' Characteristics {#sec3.1}
--------------------------------------------------

The entire cohort consisted of 685 patients with EAC were considered for analysis, in total there were 526 analyzable cases for *KRAS* (76.2%) and 461 cases for *PIK3CA* (67.3%) on the TMA. Reasons for noninformative cases included lack of tissue samples or absence of unequivocal cancer tissue in the TMA spot. Neoadjuvant treatment (either chemoradiation or chemotherapy) was administered in 403 patients (58.5%). The median follow-up for the entire cohort was 57.7 months with a calculated 5-year survival rate of 26.6% (compare [Table 1](#tbl1){ref-type="table"} with patients\' and tumor characteristics).

*KRAS* Amplification Status {#sec3.2}
---------------------------

*KRAS* amplifications were seen in 94 patients (17.1%). The amplification profile was not affected by administration of neoadjuvant treatment. Within the group of patients that underwent primary surgery, 41 patients showed *KRAS* amplification (18.1%) and 52 patients (17.7%) in the group of neoadjuvant treatment and resection (*p* = 0.909).

*KRAS* amplifications were not associated with sex (*p* = 0.719), patient\'s age (*p* = 0.416), and tumor stage (*p* = 0.880). Nodal positive patients (pN+) significantly correlated with a higher frequency of *KRAS* amplification (*p* = 0.004; [Table 1](#tbl1){ref-type="table"}). We found a correlation between *KRAS* amplification and *Her2* amplifications (*p* = 0.027) and *TP53* mutations (*p* = 0.016), respectively. A correlation between the inflammatory tumor microenvironment (CD3 positive T-cells, PD-L1, LAG3, VISTA, TIM3, IDO expression) could not be found.

*PIK3CA* Amplification Status {#sec3.3}
-----------------------------

*PIK3CA* amplifications were seen in 23 patients (5.0%). Similar amplification rates were seen within the primary surgery group (*n* = 10; 4.9%) and surgery after neoadjuvant treatment (*n* = 13; 5.1%) (*p* = 1.000).

*PIK3CA* amplifications showed no correlation with sex (*p* = 0.501), patient\'s age (*p* = 0.673), tumor stage (*p* = 0.155), lymph node metastasis (*p* = 0.669), *Her2* amplifications (*p* = 0.488), or *TP53* mutations (*p* = 0.132). In tumors with a high amount of tumor infiltrating T cells (CD3 high), the frequency of *PIK3CA* amplifications was significantly higher (11.9%) compared with T-cell low tumors (3.0%, *p* = 0.003) (compare [Figure 1](#fig1){ref-type="fig"}). A correlation with any of the analyzed immune checkpoint makers (PD-L1, LAG3, VISTA, TIM3, IDO) could not be revealed.Figure 1Esophageal adenocarcinoma showing (A) high amounts of tumor infiltrating CD3-positive T cells (brown cells) and (B) low content of CD3-positive T cells; magnification ×200.Figure 1

*KRAS* and *PIK3CA* and Prognosis {#sec3.4}
---------------------------------

Survival analysis on the entire patients\' cohort did not show any difference in OS in dependence on the KRAS status ([Figure 2](#fig2){ref-type="fig"}). However, when analyzing the patient group with primary resection, there was a significant survival difference with a worse outcome for patients with *KRAS* amplifications. The median OS for *KRAS* nonamplified patients was 64.9 months (95% confidence interval (95%CI) 29.3--100.4 months) and for amplified patients 16.2 months (95%CI, 1.2--39.5 months, *p* = 0.050). For *PIK3CA*, no difference in OS was detectable for the entire patients\' group (*p* = 0.830). Stratifying patients with and without neoadjuvant treatment did not reach a statistical significance. In patients without neoadjuvant treatment, median OS was 202.2 months (95% not achieved) compared with a median OS of 45.7 months (95% CI 26.2--65.2 months, *p* = 0.068).Figure 2Overall survival using Kaplan--Meier analyses; (A) KRAS amplification for the entire patients cohort, (B) patients with primary surgery, and (C) patients with neoadjuvant treatment before operation; (D) PIK3CA amplification for the entire patients cohort, (E) patients with primary surgery, and (F) patients after neoadjuvant treatment.Figure 2

A multivariate cox proportional hazard model revealed the presence of lymph node metastases as an independent prognostic marker (p \< 0.001), but not *KRAS* or *PIK3CA* amplifications ([Table 2](#tbl2){ref-type="table"}).Table 2Multivariate Cox-Regression Model.Table 2Hazard Ratio95% Confidence IntervalLowerUpper*p* valueSex1.6490.8913.0510.111Age group (\<65 vs. \> 65 years)1.2490.9251.6860.146Tumor stage (pT1/2 vs. pT3/4)1.3590.8562.1560.193Lymph node metastasis (pN0 vs. pN+)3.5952.485.211\<0.001*KRAS* (amplified vs. nonamplified)0.830.5671.2170.341*PIK3CA* (amplified vs. nonamplified)0.9240.4821.7710.811

Heterogeneity of Amplification {#sec3.5}
------------------------------

In *KRAS*, 15 amplified tumors showed homogeneous amplification across the tumor (both on the large tumor surface and on the h-TMA spots) and all nonamplified tumors were confirmed. In *PIK3CA*, three of the nine amplified tumors showed a heterogeneous distribution of the amplified tumor clones.

The heterogeneous distribution of *PIK3CA* also affects two cases with lymph node metastases that have both amplified and nonamplified tumor clones within the metastases.

Immunohistochemistry {#sec3.6}
--------------------

All tumors that harbored *KRAS* and *PIK3CA* amplifications also expressed KRAS and PIK3CA protein visualized by immunohistochemistry ([Figure 3](#fig3){ref-type="fig"}).Figure 3KRAS and PIK3CA gene amplification and protein expression, magnification x200. (A--C) PIK3CA positive: (A) esophageal adenocarcinoma (HE), (B) PIK3CA immunohistochemistry shows strong expression of the protein within the tumor, (C) *PIK3CA* amplification via FISH (red signals: centromer 3, green signals: *PIK3CA* gene). (D--E) PIK3CA negative: (D) Esophageal adenocarcinoma (HE), (E) PIK3CA immunohistochemistry shows no expression of the protein within the tumor, (F) *PIK3CA* nonamplified tumor via FISH with normal signal distribution pattern. (G--I) KRAS positive: (G) esophageal adenocarcinoma (HE), (H) KRAS immunohistochemistry shows strong expression of the protein within the tumor, (I) *KRAS* amplification via FISH (red signals: centromer 12, green signals: *KRAS* gene region with clusters). (J--L) KRAS negative: (J) Esophageal adenocarcinoma (HE), (K) KRAS immunohistochemistry shows no expression of the protein within the tumor, (L) *KRAS* nonamplified tumor via FISH with normal signal distribution pattern.Figure 3

Discussion {#sec4}
==========

We found higher amplification rates for *KRAS* in our large tumor population than were reported in the TCGA cohort for adenocarcinoma of the esophagus \[[@bib16],[@bib17]\], but confirm data from a recently published large study including tumors of the gastroesophageal junction \[[@bib19]\].

To describe copy-number variations, differently suitable techniques can be used. FISH analysis allows us to precisely characterize the CNGs in tumor cells. FISH analysis is actually the current standard technique for evaluation of single-gene amplifications. We defined *KRAS* amplification according to internationally accepted criteria as a ratio of \>3 and correlated our gene amplification results with protein expression of KRAS, which we determined by immunohistochemistry. We have found an excellent concordance between gene amplification and protein expression ([Figure 3](#fig3){ref-type="fig"}) and can confirm the results of a previous study describing the same concordance \[[@bib19]\].

We were able to show that *KRAS* amplified tumors represent a more aggressive subset of tumors in the primary resected, non-neoadjuvantly treated EACs mainly driven by the accumulation of lymph node metastases in this group.

This effect was no longer measurable in the neoadjuvant-treated group (combined radiochemotherapy according to the CROSS scheme or chemotherapy according to the FLOT scheme).

This is probably because of the already very unfavorable starting situation with higher clinical tumor stages and neoadjuvant pretreated pathohistological minor responders (= tumors which have an inadequate response rate with ≥10% vital tumor proportion) \[[@bib44],[@bib51]\]. The minor responders are enriched in our collection of pretreated EACs, as in the prognostically more favorable complete responders no vital tumor is detectable in the surgical specimens, thus no tumor is present for further analyses.

In the cohort of EAC, we see no difference of *KRAS* amplification rates correlating the primary resected and the neoadjuvant subgroup, indicating no influence of neoadjuvant therapy concepts on the rate of *KRAS* amplifications.

We interpret the homogeneity of *KRAS* amplification as a signal of the biological relevance of this gene multiplication, probably underlining the high therapeutic effectiveness of pathway inhibition in these tumors.

In our collection, we observe an accumulation of *TP53* mutated and *KRAS*-amplified tumors as well as coamplifications of *Her2* and *KRAS*. Future studies will need to demonstrate whether personalized therapy with combinatorial inhibition of MEK and SHP2 is effective in the subset of *KRAS* amplified EACs as discussed most recently \[[@bib19]\]. We do not see any impact on the inflammatory tumor microenvironment in *KRAS* amplified tumors.

*PIK3CA* amplification occurs less frequently than *KRAS* amplification in EACs. Primary resected patients with *PIK3CA* amplifications show a favorable prognosis; however, statistical significance is not achieved (*p* = 0.068). Conflicting results are found in the literature in esophageal squamous cell carcinoma. One work finds an unfavorable prognosis in *PIK3CA* amplifications, another study shows a favorable prognosis in activating *PIK3CA* mutations \[[@bib52],[@bib53]\]. To our knowledge, nothing is known about the prognostic significance of *PIK3CA* amplification in EAC. A study on gastric carcinoma in Asian patients showed an unfavorable prognosis and a very high percentage of more than 60% *PIK3CA*-amplified gastric tumors \[[@bib24]\]. Considering the inflammatory tumor environment, *PIK3CA*-amplified tumors have a significant accumulation of T lymphocytes. We observed in our tumor collection (data not published), as well as other studies, a favorable prognosis of T cell--rich inflammation in EAC \[[@bib36], [@bib37], [@bib38]\]. The T-cell enrichment in the microenvironment may explain the tendency to the favorable prognosis of *PIK3CA*-amplified EACs.

This interesting relationship between gene amplification, tumor cell--associated cancer pathway activation, and effect on the inflammatory tumor microenvironment could be explained by the PIK-AKT pathway--mediated activation of the NF-kappaB pathway, as previously described on colitis-associated colon carcinoma or on ovarian carcinoma \[[@bib30],[@bib31]\]. The activation of AKT is linked to an accumulation of inflammatory cells in the tumor microenvironment such as CD8 + T lymphocytes, whereas cyclooxygenase 2, which is also typically found on activation of this pathway, can regulate the synthesis of prostaglandin E~2~ (PEG~2~) leading to an accumulation of certain T cells via its PEG~2~ receptor \[[@bib32],[@bib33]\]. Because a T cell--rich tumor microenvironment may be detrimental to the survival of the tumor, it is useful to establish escape mechanisms against T-cell inflammation. The upregulation of specific immunosuppressive checkpoint markers such as PD-L1, LAG3, IDO, TIM3, and VISTA may be helpful.

Therefore, we examined these checkpoint markers in our tumor population, but see no relation of an accumulation of these checkpoint markers and T cell--rich tumors with amplification of *PIK3CA*. Apparently, T cell--rich *PIK3CA*-amplified tumors are a subtype of EAC choosing other strategies of immune escape. Further studies need to clarify the interactions of copy-number variations and the tumor microenvironment.

Possible limitations of our work are the retrospective nature of the analyzes, the restriction to surgical specimens, and the accumulation of minor responders in our group of neoadjuvant-treated patients. Statements on the distribution of *KRAS*- or *PIK3CA*-amplified tumors in nonpretreated biopsy specimens and correlation to complete responders after neoadjuvance cannot be made.

Conclusions {#sec5}
===========

In conclusion, this work on a very large collection of EAC shows that *KRAS* amplification is prognostically unfavorable in primary resected EACs, whereas the *PIK3CA*-amplified genotype with T cell--rich inflammatory tumor microenvironment shows a tendency to a better OS.

Future studies must show to what extent these two different tumor subgroups can be therapeutically influenced in the EAC. Thus, in the subgroup of *KRAS*-amplified EACs a dual inhibition of MEK and SHP2 and in the subgroup of *PIK3CA*-amplified EACs an immune checkpoint blockade may prove to be particularly promising.
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